SLS 8-K: Secondary offering
SELLAS Life Sciences Group
Filed with the SEC on · accession 0001104659-26-130331
SLS filed a 8-K (current report) with the SEC on Nov 20, 2026. A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more.
Summary of the filing
SELLAS Life Sciences Group entered into an underwriting agreement for an underwritten public offering of 11,538,462 shares of common stock at $13.00 per share, with an additional 1,730,769 option shares exercised in full, raising approximately $161.8 million in net proceeds.
Key details
✦ Ask GOAX AI about this filing — what it means for SLS, what changed since its last filings and what to watch next.
Try it free for 7 days🔔 Want to stay updated on new SEC filings for SLS?
Click hereFrequently asked questions
What did SLS file with the SEC on Nov 20, 2026?
SLS filed a 8-K (Secondary offering). SELLAS Life Sciences Group entered into an underwriting agreement for an underwritten public offering of 11,538,462 shares of common stock at $13.00 per share, with an additional 1,730,769 option shares exercised in full, raising approximately $161.8 million in net proceeds.
What does a secondary offering mean for SLS stock?
New shares dilute existing holders and are often sold at a discount to the market price.
How do I read a 8-K?
A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more. The "Item" number tells you the topic (e.g. 2.02 results, 5.02 executive change, 1.01 new agreement, 1.03 bankruptcy). Exhibits (99.1 press release) usually hold the details.
Why are SEC filings important?
Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 8-K (current report): A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more.
Other SLS SEC filings
- 424B5 · Secondary offeringNov 19, 2026
- 8-K · Fda approvalNov 17, 2026
- 424B5 · Secondary offeringNov 17, 2026
- 8-K · SEC filingNov 12, 2026
- 10-Q · SEC filingNov 12, 2026
- SCHEDULE 13G · SEC filingNov 10, 2026
- SCHEDULE 13G/A · SEC filingOct 27, 2026
- 10-Q · SEC filingAug 11, 2026
- 8-K · SEC filingAug 11, 2026
- 8-K · SEC filingJul 27, 2026
Get alerts when SLS files with the SEC, plus live charts, key levels and news for 13,000+ stocks.
Try SEPT free for 7 days